Donato Celeste M, Zhang Zheng Andrew, Donker Nicole C, Kirkwood Carl D
Enteric Virus Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia; Department of Microbiology, La Trobe University, Melbourne, Australia.
Enteric Virus Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia.
Infect Genet Evol. 2014 Dec;28:398-412. doi: 10.1016/j.meegid.2014.05.020. Epub 2014 May 24.
The introduction of rotavirus vaccines Rotarix® and RotaTeq® into the Australian National Immunisation Program in July 2007 has resulted in a dramatic decrease in the burden of rotavirus disease. G2P[4] strains became the dominant genotype Australia-wide during the 2010-2011 surveillance period and for the first time since vaccine introduction, a higher proportion were isolated in jurisdictions using RotaTeq® vaccine compared to locations using Rotarix®. Phylogenetic analysis of the VP7 gene of 32 G2P[4] strains identified six genetic clusters, these distinct clusters were also observed in the VP4 gene for a subset of 12 strains. The whole genome was determined for a representative strain of clusters; A (RVA/Human-wt/AUS/SA066/2010/G2P[4]), B (RVA/Human-wt/AUS/WAPC703/2010/G2P[4]), C (RVA/Human-wt/AUS/MON008/2010/G2P[4]) and E (RVA/Human-wt/AUS/RCH041/2010/G2P[4]). All of the strains possessed the archetypal DS-1 like genome constellation G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2. Three of the strains, SA066, MON008 and WAPC703 clustered together and were distinct to RCH041 for all 11 genes. The VP7 genes of 31/32 of the strains characterized in this study possessed five conserved amino acid substitutions when compared to the G2 VP7 gene present in the RotaTeq® vaccine. Three of the substitutions were in the VP7 antigenic regions A and C, the substitutions A87T, D96N and S213D have been reported in the majority of G2P[4] strains circulating globally over the previous decade. These changes may have improved the ability of strains to circulate in settings of high vaccine use.
2007年7月轮状病毒疫苗Rotarix®和RotaTeq®被纳入澳大利亚国家免疫规划后，轮状病毒疾病负担显著下降。在2010 - 2011年监测期间，G2P[4]毒株成为全澳大利亚的优势基因型，自引入疫苗以来首次出现，与使用Rotarix®疫苗的地区相比，在使用RotaTeq®疫苗的辖区分离出的该毒株比例更高。对32株G2P[4]毒株的VP7基因进行系统发育分析，确定了6个基因簇，在12株毒株的子集的VP4基因中也观察到了这些不同的基因簇。测定了各基因簇代表性毒株的全基因组；A（RVA/Human-wt/AUS/SA066/2010/G2P[4]）、B（RVA/Human-wt/AUS/WAPC703/2010/G2P[4]）、C（RVA/Human-wt/AUS/MON008/2010/G2P[4]）和E（RVA/Human-wt/AUS/RCH041/2010/G2P[4]）。所有毒株均具有典型的DS-1样基因组星座G2-P[4]-I2-R2-C2-M2-A2-N2-T2-E2-H2。其中3株，SA066、MON008和WAPC703聚集在一起，在所有11个基因上与RCH041不同。与RotaTeq®疫苗中存在的G2 VP7基因相比，本研究中鉴定的32株毒株中的31株的VP7基因具有5个保守氨基酸取代。其中3个取代位于VP7抗原区域A和C，取代A87T、D96N和S213D在过去十年全球流行的大多数G2P[4]毒株中均有报道。这些变化可能提高了毒株在疫苗高接种率环境中的传播能力。
